Benchmark Comments On BRLI Meetings

On March 16, Benchmark hosted Bio-Reference Laboratories Inc.'s BRLI management on investor meetings in Minneapolis.

“We believe strong trends will continue in F2011, unimpeded by the unfavorable weather that suppressed F1Q revenue and impacted EPS approximately $0.03,” Benchmark writes. “By year-end we anticipate tangible revenue contribution from the prenatal business that was launched in January. By this fall we anticipate BRLI will launch an MGH co-branded comprehensive solid tumor sequencing test.

“We look for spending growth to moderate as these new programs transition from development to launch. We model this driving earnings leverage for two to three years.”

Bio-Reference Laboratories closed Thursday at $21.90.